IBB250110C155000
- 0.00
- 0.000.00%
iShares Biotechnology ETF Newsroom
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus
Merck Downgraded by Truist to Hold Over Growth Concerns
Sector Update: Health Care Stocks Rise Premarket Wednesday
Asher Bio Announces Clinical Trial Collaboration And Supply Agreement With Amgen On Etakafusp Alfa In Combination With Bispecific T-cell Engager In Patients With Small Cell Lung Cancer
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of FOMC Meeting Minutes
Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
Biogen Analyst Ratings
Amgen Analyst Ratings
Solid Biosciences Stock Jumps 11% Post-market on FDA Update
Looking Into Gilead Sciences's Recent Short Interest
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Vertex Grapples With Bearish Chart As Death Cross Emerges
Alnylam Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
FDA Issues Draft Guidance on Developing Weight Loss Drugs
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Argenx Analyst Ratings
Orna Therapeutics Enters Three-year Strategic Research Collaboration With Vertex Pharmaceuticals; Orna To Receive $65M Upfront Payment And Is Eligible To Receive Up To $635M Milestones
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today